Your session is about to expire
← Back to Search
High-Dose Aflibercept for Diabetic Macular Edema (PHOTON Trial)
PHOTON Trial Summary
This trial is testing if a more concentrated dose of aflibercept, given less often, is as effective as the current standard dose given more often, in terms of improve vision.
PHOTON Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowPHOTON Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 106 Patients • NCT04126317PHOTON Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received ocriplasmin treatment in my eye.My eye condition is worsening due to diabetes.I have swelling in the center of my retina due to diabetes.You are willing and able to comply with clinic visits and study-related procedures.I completed 96 weeks in the study without other DME treatments besides the study treatment.I completed week 96 of the study without any DME treatment other than the study's.I have never received experimental eye injections.My vision in the study eye is between 20/32 and 20/320 due to diabetic macular edema.I have swelling in the retina not caused by diabetes.I haven't had specific eye treatments in the last 3-4 months.
- Group 1: High-Dose aflibercept Q12
- Group 2: High-Dose aflibercept Q16
- Group 3: aflibercept Q8
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you tell me how many different facilities are running this clinical trial?
"Currently, there are 86 sites running this clinical trial. They are based in New york, Kingston, Cleveland and other locations. To reduce the amount of travelling required, it is best to choose a location near you."
Have any other research groups looked into the effects of high-dose aflibercept?
"M D Anderson Cancer Center pioneered high-dose aflibercept research in 2014. Currently, there are 227 completed studies and 49 ongoing clinical trials. New york, New York is one of the many places where high-dose aflibercept's efficacy is being investigated."
How many test subjects are included in the sample size for this research?
"As of now, this particular clinical trial is not recruiting any more participants. The trial was first posted on 6/29/2020 and was last edited on 11/2/2022. If you are interested in other studies, 1667 clinical trials for type 2 diabetes mellitus and 49 trials for High-dose aflibercept are still recruiting patients."
What condition does High-dose aflibercept usually target?
"Wet age-related macular degeneration (WAMD) is often managed with high-dose aflibercept. This treatment option can also be successful in cases of macular edema, diabetic macular edema (DME), and general macular degeneration."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger